drugset / Trial / NCT00010192
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-2 may kill more cancer cells. Phase I trial to study the effectiveness of rituximab plus interleukin-2 in treating patients who have hematologic cancer.
Timeline
- Start
- 2000-12
- Primary completion
- 2003-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |